Nefazodone in the Treatment of Social Phobia

Emory University

Status and phase: Completed; Phase 4

Conditions: Social Anxiety Disorder (SAD)

Treatments: Drug: Nefazodone

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00231348

0707-1997

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).

Full description

The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• DSM-IV diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65

Exclusion criteria

• A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)